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Purpose: To compare the efficacy and safety of Sulosin D (PACIFICPHARMA, Korea) 
and Harnal D (ASTELLAS PHARMA KOREA, Korea) in treating patients with lower 
urinary tract symptoms associated with benign prostatic hyperplasia (BPH). 
Materials and Methods: This randomized, controlled, open-label, multicenter non-in-
feriority study was conducted at four sites in Korea. We randomly assigned 123 patients 
with an International Prostate Symptom Score (IPSS) ≥12 to receive either Sulosin 
D or Harnal D treatment for 8 weeks. The primary outcome was the mean change in 
IPSS from baseline to endpoint. Secondary outcomes were the mean change from base-
line to endpoint in IPSS quality of life subscores, maximum uroflowmetry (Qmax), and 
post-voiding residuals (PVR).
Results: In all, 123 patients were randomly assigned (60 Sulosin D and 63 Harnal D). 
The changes in the total IPSS from baseline in the Sulosin D- and Harnal D-treated 
groups were -4.97 and -4.03, respectively. There were significant decreases compared 
with baseline in both groups. The mean difference (Sulosin D - Harnal D) was -0.91 (with 
a two-sided 90% confidence interval), inferring that Sulosin D was not inferior to Harnal 
D. The mean changes in the IPSS subscore, Qmax, and PVR from baseline were com-
parable between the groups (both p＞0.05). During the treatment periods, the incidence 
of adverse events was 23.33% and 34.92% in the Sulosin D and Harnal D groups, re-
spectively (p=0.1580).
Conclusions: We demonstrate the non-inferiority of Sulosin D to Harnal D in patients 
with lower urinary tract symptoms associated with BPH.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) are problematic in 
daily life and lower the quality of life in affected people. 
Benign prostatic hyperplasia (BPH) is a common cause of 
LUTS, and, as the average male life expectancy continues 
to increase, the number of males suffering from voiding dif-
ficulty secondary to BPH will increase accordingly [1]. As 
males age, their probability of developing LUTS, for which 
BPH is the most common cause, increases [2]. Treatment 
of LUTS includes watchful waiting, pharmacotherapy us-
ing α1-adrenergic receptor (AR) antagonists and 5α-reduc-
tase inhibitors in moderate to mild cases, and surgical ther-
apy such as transurethral resection of the prostate for se-
vere cases [3,4]. In terms of medical therapy, the use of 
α1-AR antagonists is the recommended treatment [5]. Korean J Urol 2012;53:178-183
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However, α1-AR antagonists act not only in the lower uri-
nary tract, but also in other tissues such as the vasculature, 
and cause cardiovascular side effects [6,7]. Tamsulosin, a 
highly selective α1A-AR antagonist that is currently used, 
does not significantly decrease systolic and diastolic pres-
sure [8].
Harnal D (astellas pharma Korea Inc., Seoul, Korea) was 
the original brand name of tamsulosin in Korea, and it was 
considered a reasonable clinical recommendation for pa-
tients with BPH-associated LUTS. The objectives of this 
study were to verify that Sulosin D (Pacificpharma Co., 
Seoul, Korea), the generic version of tamsulosin, is not in-
ferior to Harnal D in patients with BPH. Our comparison 
was based on the efficacy and safety results of a dose-find-
ing study conducted in Korean patients [9].
MATERIALS AND METHODS
1. Participants
Male patients aged ≥40 years and ＜80 years with LUTS 
were recruited from four sites in Korea. The eligibility cri-
teria included LUTS for at least 6 months, a total score of 
at least 12 on the International Prostate Symptom Score 
(IPSS), and a voluntary signature on informed consent 
forms. The institutional review board at each of the partic-
ipating clinical centers approved the study, and all the men 
provided written informed consent. 
The exclusion criteria included suspicious hyper-
sensitivity to α-AR antagonists; a disease causing LUTS 
(urinary tract stone, urethral stricture, urinary tract in-
fection, primary renal disease, neurogenic bladder, prosta-
titis); a history of prostate cancer, bladder cancer, previous 
prostate surgery, urethral reconstruction, transurethral 
resection of the prostate, or hyperthermia treatment; se-
rum PSA ≥4 ng/ml (a patient whose PSA was ≥4 ng/ml 
and ＜10 ng/ml with no malignancy as confirmed by pros-
tate biopsy could be included within 1 year); use of α-AR 
antagonists or anticholinergics in the previous 2 weeks; 
medicated with 5α-reductase inhibitors (a patient taking 
a medication at a stable dose before 12 weeks could be in-
cluded); medicated with vasopressin or desmopressin (a 
patient taking these medications at a stable dose before 4 
weeks could be included); medicated with SSRI or anti-
psychotic drugs (a patient taking a medication at a stable 
dose before 12 weeks could be included); a post-void re-
sidual (PVR) urine volume of ＞150 ml; known moderate 
cardiovascular disease; orthostatic hypotension; hypoten-
sion; known geriatric Alzheimer’s disease; or participation 
in another clinical trial within 4 weeks.
2. Interventions 
The typical dose of tamsulosin recommended in Korea is 
0.2 mg/day, and this regimen was adopted in this study. We 
randomly assigned participants at a 1:1 ratio to receive 0.2 
mg of Sulosin D or 0.2 mg Harnal D once daily for 8 weeks. 
A permuted-block randomization procedure with ran-
domly assigned block sizes of four and six was used. There 
were four clinic visits during which data for the primary 
and secondary outcome measures were collected. Visit 1 in-
volved screening and collection of baseline data, visit 2 in-
volved randomization and baseline data, visit 3 was the 
4-week evaluation, and visit 4 was the 8-week evaluation 
of the primary endpoint. Adverse events data were col-
lected on visits 3 and 4.
3. Outcomes
The primary endpoint for efficacy was a comparison of the 
change in IPSS from baseline in the experimental groups 
with that in the control group. The secondary endpoints 
were changes in maximal uroflowmetry (Qmax), post-void-
ing residual (PVR), and quality-of-life (QoL) from baseline. 
The changes in IPSS subscores were also compared. The pa-
tient’s perception of benefit and global response assessment 
were compared. Comparisons of efficacy parameters within 
groups at the endpoint and at baseline were conducted by 
using RMANOVA. Comparisons of efficacy parameters be-
tween groups were conducted by using ANCOVA.
The difference in IPSS change between the two groups from 
baseline to 8 weeks was calculated. The non-inferiority mar-
gin of Δ  was set at -2.4. In other words, non-inferiority is in-
dicated if the lower limit of a one-sided 95% confidence inter-
val for the difference of the change in the IPSS falls above this 
cutoff. The estimated IPSS difference score of -4.8 was based 
on previous studies of the efficacy of tamsulosin in Asian BPH 
patients [10]. The number of patients required to verify the 
non-inferiority of Sulosin D compared with Harnal D with a 
one-sided statistical significance level of 5% and a power of 
80% was calculated to be 52 patients per group (using the 
formula,  ). We anticipated that about 
15% of enrolled patients would be ineligible. Therefore, 122 
patients (61 per study group) were recruited. All results are 
presented as means±standard deviations.
RESULTS
Ultimately, 123 of the 130 men who agreed to participate 
at the beginning of the screening phase were eligible. 
Efficacy variables were analyzed on an intent-to-treat 
basis. A flow diagram of patient allocation is depicted in 
Fig. 1. The baseline characteristics of each group are pre-
sented in Table 1. There were no significant differences be-
tween the two groups except in QoL and the storage sum 
of the IPSS. The mean IPSS was slightly high in the Sulosin 
D group, but the difference was not significant (18.87± 5.62 
vs. 17.16±5.22, p=0.1179). Cardiovascular disease and 
gastrointestinal disease, respectively, were the first and 
second most commonly reported concomitant diseases in 
both groups. 
The mean changes in primary outcomes at 8 weeks from 
baseline are summarized in Table 2. After 8 weeks of treat-
ment, patients in the two groups exhibited a significant re-
duction in IPSS (Sulosin D, -4.97 and Harnal D, -4.03; p
＜0.0001 for each intra-group comparison). The mean 
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FIG. 1. Flow diagram of patient alloca-
tion. ITT, intention-to-treat; PP, per- 
protocol.
TABLE 1. Baseline demographics in the two groups 
Variable
Sulosin D
n=60
Harnal D
n=61
p-value
Age (yr)
Prevalence period of BPH (mo)
Prevalence period of LUTS (mo)
PSA, ng/ml
Prostate volume, g
IPSS, total
    Storage sum
    Voiding sum
Quality of life
62.98±7.47
  18.42±31.78
  53.27±56.66
  1.17±0.82
31.11±7.35
18.72±5.62
  7.42±3.02
11.30±4.45
  4.45±0.85
61.70±7.95
  30.30±47.54
  44.45±41.81
  1.41±1.26
  32.00±11.66
17.16±5.22
  6.18±2.96
10.98±4.02
  4.05±0.78
0.3642
0.1676
0.3356
0.2132
0.6320
0.1179
0.0249
0.6821
0.0081
Values are presented as mean±SD.
BPH, benign prostatic hyperplasia; LUTS, lower urinary tract symptoms; PSA, prostate-specific antigen; IPSS, International Prostate 
Symptom Score. 
changes in IPSS at 8 weeks were not significantly different 
between the Sulosin D and Harnal D groups (p=0.9042). 
The mean difference in IPSS change over the 8-week 
treatment period between the two groups was 0.93±6.11 
(Harnal D-Sulosin D) in the intent-to-treat cohort, with the 
90% confidence interval ranging from -0.91 to 2.77. The 
lower 90% confidence limit was greater than the prescribed 
Δ(-2.4) margin. Thus, the non-inferiority of Sulosin D to 
Harnal D with respect to IPSS improvement was confir-
med. 
Significant improvements in IPSS subscores and QoL 
were observed by the end of treatment in both the Sulosin 
D and Harnal D groups, with the exception of frequency and 
urgency in the Harnal D group (p=0.1825 and 0.2115, re-
spectively). None of the changes in subscores at 8 weeks 
were significantly different between the two groups. 
Moreover, Qmax and PVR were not significantly different 
(Table 3). The patient perception of benefit after treatment 
was significantly different in the two groups (Fig. 2). The 
global response assessment of BPH treatment was not sig-Korean J Urol 2012;53:178-183
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TABLE 2. Comparison of the International Prostate Symptom Score (IPSS) between the two groups at baseline and 8 weeks
Sulosin D
n=60
Harnal D
n=61
p-value
IPSS, total at
    Baseline
    8 wk
Change in total IPSS at 8 wk
% Reduction in total IPSS at 8 wk
Storage sum at
    Baseline
    8 wk
Change in storage sum at 8 wk
% Reduction in storage sum at 8 wk
Voiding sum at
    Baseline
    8 wk
Change in voiding sum at 8 wk
% Reduction in voiding sum at 8 wk
Quality of life at
    Baseline
    8 wk
Quality of life at 8 wk
% Reduction in quality of life at 8 wk
18.72±5.62
13.75±6.40
-4.97±6.80
-24.20±35.12
  7.42±3.02
  5.57±2.81
-1.85±2.89
-18.09±41.92
11.30±4.45
  8.18±4.32
-3.12±5.10
-22.71±48.53
  4.45±0.85
  3.12±1.38
  3.12±1.38
-28.22±33.06
17.16±5.22
13.13±5.55
-4.03±5.34
-21.46±33.45
  6.18±2.96
  5.28±2.56
-0.90±2.43
  -2.28±60.92
10.98±4.02
  7.85±4.09
-3.13±3.85
-23.40±45.29
  4.05±0.78
  3.03±1.18
  3.03±1.18
-23.99±28.63
0.1179
0.8723
0.9042
0.9191
0.0249
0.4172
0.4172
0.4403
0.6821
0.7779
0.7779
0.7664
0.0081
0.7293
0.7293
0.9273
Values are presented as mean±SD.
TABLE 3. Comparison of International Prostate Symptom Score subscores, Qmax, and PVR at 8 weeks 
Sulosin D
n=60
Harnal D
n=61
p-value
Change in subscore at 8 wk
Empty
Frequency
Intermittency
Urgency
Weak stream
Hesitancy
Nocturia
% Reduction in subscore at 8 wk
Empty
Frequency
Intermittency
Urgency
Weak stream
Hesitancy
Nocturia
Qmax (ml/s)
Baseline
8 wk
PVR, ml
Baseline
8 wk
-0.68±1.73
-0.60±1.30
-0.70±1.65
-0.38±1.35
-1.05±1.73
-0.68±1.86
-0.87±1.37
-10.38±79.19
-12.17±56.52
  -9.91±84.68
-16.64±62.90
-24.97±46.93
-20.52±82.48
-23.64±51.08
13.51±5.48
15.85±6.85
 24.38±26.30
 25.43±30.77
-0.52±1.52
-0.28±1.61
-0.87±1.40
-0.21±1.32
-0.90±1.33
-0.84±1.57
-0.41±1.15
-11.29±77.17
-10.47±90.39
-25.98±60.33
  -2.91±99.01
-19.75±50.25
-26.07±74.35
-10.73±61.66
13.24±5.62
15.49±6.90
 28.85±35.00
 21.49±26.10
0.5932
0.2741
0.5443
0.4849
0.5981
0.6268
0.0489
0.9508
0.1032
0.2448
0.4161
0.5599
0.7192
0.2212
0.7916
0.8515
0.5385
0.2258
Values are presented as mean±SD.
Qmax, maximum uroflowmetry; PVR, post-voiding residual. 
nificantly different in the two groups (Fig. 3). 
During the treatment periods, adverse events were re-
ported in 23.33% and 34.92% of the Sulosin D and Harnal 
D groups, respectively, but the incidence of adverse events 
did not differ significantly between the groups (p=0.1580). 
However, 13.33% and 11.48% of the Sulosin D and Harnal Korean J Urol 2012;53:178-183
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FIG. 2. Comparison of patient’s percep-
tion of treatment benefit between the 
two groups at 8 weeks.
FIG. 3. Comparison of global response assessment of treatment 
of benign prostatic hyperplasia between the two groups after 8 
weeks of treatment (p=0.8132). 
D groups had adverse events that were considered by the 
investigator as possibly or probably related to medication.
Only one (1.67%) and two (3.23%) patients in the Sulosin 
D and Harnal D groups, respectively, withdrew from the 
study due to adverse events. Almost all of these adverse 
events resolved without the discontinuation of treatment. 
There were two patients in each group who discontinued 
treatment. There were no moderate or severe adverse 
events in either group. The most common adverse event 
was dizziness (9.09% with Sulosin D vs. 5.88% with Harnal 
D). On the basis of the logistic regression analysis, we found 
that previous medication history and concomitant medi-
cation were significantly associated with adverse events 
(p=0.0442 and p=0.0375, respectively). Prostate size, 
treatment group, age, and serum PSA were not associated 
with the occurrence of adverse events. 
The mean change in systolic blood pressure from base-
line to the end of treatment did not differ significantly be-
tween the two groups (Sulosin D, 1.31±12.30 vs. Harnal D, 
-1.70±11.79, p=0.1738). The change in diastolic pressure 
was significantly higher in the Harnal D group (Sulosin D, 
1.44±8.77 vs. Harnal D, -1.80±6.71; p= 0.0251). There was 
a significant increase in the pulse rate in the Harnal D 
group (baseline, 69.33±10.61 vs. 8 weeks 73.54±9.64; p= 
0.0002), but there was no significant difference between 
the two groups (Sulosin D, 1.92±10.38 vs. Harnal D, 
4.21±8.45; p=0.1853).
DISCUSSION
The present study showed that Sulosin D was not inferior 
to Harnal D in patients with LUTS symptoms associated 
with BPH. The changes in total IPSS, QoL, IPSS subscores, 
Qmax, and PVR after treatment were all comparable be-
tween the groups. The within-group improvements in total 
IPSS score were highly statistically significant (both p-val-
ues ＜0.0001) for the Sulosin D and Harnal D groups. 
Significant improvements within groups were similar be-
tween the groups (p=0.8644). Moreover, the change in total 
IPSS score in both groups was greater than 4 points, which 
can be considered perceptible improvement [11]. At base-
line, two parameters were statistically different between 
the two groups: QoL and the storage sum of the IPSS. 
Because of these parameters, we compared the primary 
endpoint and secondary endpoints by both the changes in 
score and those in reduction percentages, both within 
groups and between groups for each comparison.
Abnormal ejaculation occurred with a greater incidence 
during tamsulosin 0.4 mg treatment than with placebo. 
The incidence of abnormal ejaculation with tamsulosin 
was around 5% to 11% in the US studies [12]. In our study, 
the abnormal ejaculation rates were 3% and 1.6% in the 
Sulosin D and Harnal D groups. The abnormal ejaculation 
rate in our study was less than that of the US studies.
In the patient’s perception of benefit, there was a statisti-
cally significant difference between the two groups. 
However, in the global response assessment of treatment 
of BPH, there were no significant differences between the Korean J Urol 2012;53:178-183
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two groups, and more than half of the subjects answered 
that they were improved compared with before treatment.
A bioequivalence test has been required since 1989 when 
generic drugs were approved by the Korea Food and Drug 
Administration (KFDA) [13]. A bioequivalence study pro-
vides important information to ensure the availability of 
safe and effective medicines to patients. The bioequi-
valence measure is frequently expressed in terms of sys-
temic exposure measures, such as the area under the plas-
ma concentration-time curve and maximum concentra-
tion. Bioequivalence assesses the relative bioavailability 
of two drug products and focuses on comparative drug prod-
uct performance [14]. This is established in small bio-
equivalence studies, which are single-dose crossover stud-
ies in healthy subjects comparing peak concentration and 
total drug exposure during treatment with either reference 
or generic test formulations [15]. For generic approval, the 
distributions of the ratio of peak concentrations and con-
centrations measured over time for a reference compared 
with the test formulation must be between 80% and 125%. 
However, there is no evidence that bioequivalence trans-
lates to equality in terms of clinical efficacy. 
More than 140 generic BPH drug formulations have been 
approved through the KFDA. Generics account for about 
39% of BPH medications in Korea. In terms of pharmaceut-
ical costs, generics account for about 37% of BPH medi-
cation costs. In Korea, generic drug costs are 80% of brand-
ed drug costs. If bioequivalence indicates equality with re-
spect to clinical efficacy, clinicians will consider using ge-
neric drugs. As mentioned earlier, all generics have not 
been proven to be equivalent to the original brand drugs.
A limitation of our study was that it did not include a pla-
cebo group. To confirm the efficacy of a generic, a study 
should determine whether it is superior to placebo and not 
inferior to the original drug. This hypothesis was the best 
for evaluating the efficacy of the Sulosin D, but our study 
did not have a placebo group.
There has not been an equivalence study or a non-in-
feriority clinical trial for BPH medication. This study may 
be the first clinical trial to assess the non-inferiority of a 
generic BPH medication compared with the original drug. 
If other generic BPH drugs demonstrate equality or non-in-
feriority, more urologists will prescribe generics, which is 
likely to result in a decrease in pharmaceutical costs. 
CONCLUSIONS
A highly selective α1-AR antagonist, Sulosin D 0.2 mg once 
daily, was not inferior to Harnal D in patients with moder-
ate to severe LUTS associated with BPH. Thus, Sulosin D 
should be considered an effective and safe treatment for 
BPH.
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